PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Atenolol - Hypertension
PAD Profile : Atenolol - Hypertension
Traffic Light Status
Status 1 of 1.
Status :
Green
Important
Preferred
Formulations :
- Oral solution
- Tablets
Important Information :
Step 4 of the hypertension pathway. Bisoprolol / atenolol are the preferred, cardio-selective beta blockers for hypertension.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Aliskiren
- Bendroflumethiazide
- Candesartan cilexetil
- Eprosartan
- Indapamide
- Irbesartan
- Losartan potassium
- Olmesartan medoxomil
- Valsartan
- Ramipril
- Amlodipine
- Lisinopril
- Bisoprolol fumarate
- Doxazosin mesilate
- Diltiazem hydrochloride
- Nifedipine
- Perindopril erbumine
- Telmisartan
- Moxonidine
- Co-tenidone (Atenolol/chlortalidone)
- Enalapril maleate
- Quinapril hydrochloride
- Nebivolol
- Perindopril arginine
- Metolazone
- Azilsartan medoxomil
- Captopril
- Lercanidipine hydrochloride
- Nicardipine hydrochloride
- Chlortalidone
- Spironolactone
- Carvedilol
- Celiprolol hydrochloride
- Metoprolol tartrate
- Propranolol hydrochloride
- Prazosin hydrochloride
- Clonidine hydrochloride
- Hydralazine hydrochloride
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
07 August 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.
Associated BNF Codes
02. Cardiovascular System
02.04.00. Beta-adrenoceptor blocking drugs